The impact of increased utilization of HIV drugs on longevity and medical expenditure: An assessment based on aggregate US time-series data

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 6, Issue 4, 2006, Pages 425-436

  Lichtenberg, Frank R ^a  

^a The Sanford C Bernstein Co Center for Leadership and Ethics   (United States)

Author keywords

HIV AIDS; Hospitalization; Innovation; Life expectancy; Medical expenditure; Mortality; Pharmaceuticals

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG UTILIZATION; ECONOMIC ASPECT; HEALTH CARE COST; HOSPITAL COST; HOSPITAL DISCHARGE; HOSPITAL UTILIZATION; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EXPECTANCY; MEDICAID; MORTALITY; PREDICTION; STATISTICAL ANALYSIS; SURVIVAL; UNITED STATES;

EID: 33748107375     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.6.4.425     Document Type: Article

References (4)

1. Freedberg KA, Losina E, Weinstein MC et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N. Engl. J. Med. 344(11), 824-831 (2001).
2. Lai DJ, Tarwater PM, Hardy RJ. Measuring the impact of HIV/AIDS, heart disease and malignant neoplasms on life expectancy in the USA from 1987 to 2000. Public Health 120(6), 486-492 (2006).
3. Greene, William H. Econometric Analysis Third Edition. Prentice-Hall, NJ, USA (1997).
4. Murphy KM, Topel RH. The Economic Value of Medical Research. In: Measuring the Gains from Medical Research: An Economic Approach, Murphy KM, Topel RH (Eds), University of Chicago Press, IL, USA (2003).